Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients

被引:26
|
作者
Koh, Hui Kai [1 ]
Chai, Zi Teng [2 ]
Tay, Hui Wen [1 ]
Fook-Chong, Stephanie [3 ]
Choo, Karen J. L. [2 ]
Oh, Choon Chiat [2 ]
Yeo, Yi Wei [2 ]
Koh, Hong Yi [2 ]
Pang, Shiu Ming [2 ]
Lee, Haur Yueh [2 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Dermatol, Outram Rd, Singapore 169608, Singapore
[3] Singapore Gen Hosp, Hlth Serv Res Unit, Div Med, Singapore, Singapore
关键词
adverse drug reactions; bacteremia; diagnostic markers; microbiology; risk factors; sepsis; Stevens-Johnson syndrome; toxic epidermal necrolysis; RETROSPECTIVE ANALYSIS; UNKNOWN ORIGIN; PROCALCITONIN; EPIDEMIOLOGY; MULTIFORME; GUIDELINES; MANAGEMENT; FEVER;
D O I
10.1016/j.jaad.2019.05.096
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Sepsis is the main cause of death in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Objectives: Our aim was to identify admission risk factors predictive of bacteremia and the accompanying clinical or biochemical markers associated with positive blood cultures. Methods: A retrospective cohort study over a 14-year period (2003-2016) was performed. Results: The study included 176 patients with SJS (n = 59), SJS-TEN overlap (n = 51), and TEN (n = 66). During hospitalization, bacteremia developed in 52 patients (29.5%), who experienced poorer outcomes, including higher intensive care unit admission (P < .0005), longer length of stay (P < .0005), and higher mortality (P < .0005). There were 112 episodes of bacteremia, and isolates included Acinetobacter baumannii (27.7%, n = 31) and Staphylococcus aureus (21.4%, n = 24). On multivariate analysis, clinical factors present at admission that were predictive of bacteremia included hemoglobin <= 10 g/dL (odds ratio [OR] 2.4, confidence interval [CI] 2.2-2.6), existing cardiovascular disease (OR 2.10, CI 2.0-2.3), and body surface area involvement >= 10% (OR 14.3, CI 13.4-15.2). The Bacteremia Risk Score was constructed with good calibration. Hypothermia (P = .03) and procalcitonin >= 1 mu g/L (P = .02) concurrent with blood culture sampling were predictive of blood culture positivity. Limitations: This is a retrospective study performed in a reference center. Conclusion: Hemoglobin <= 10 g/dL, cardiovascular disease, and body surface area involvement >= 10% on admission were risk factors for bacteremia. Hypothermia and elevated procalcitonin are useful markers for the timely detection of bacteremia.
引用
收藏
页码:686 / 693
页数:8
相关论文
共 50 条
  • [41] Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    Jaller, Jose A.
    McLellan, Beth N.
    Balagula, Yevgeniy
    CURRENT DERMATOLOGY REPORTS, 2020, 9 (01) : 58 - 72
  • [42] Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis
    Levi, Natacha
    Bastuji-Garin, Sylvie
    Mockenhaupt, Maja
    Roujeau, Jean-Claude
    Flahault, Antoine
    Kelly, Judith P.
    Martin, Elvira
    Kaufman, David W.
    Maison, Patrick
    PEDIATRICS, 2009, 123 (02) : E297 - E304
  • [43] Upper airway involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis
    Bhullar, Harmeet K.
    Aung, Ar Kar
    Graudins, Linda
    Ihle, Josh
    Gin, Douglas
    Cleland, Heather
    Teh, Bing Mei
    BURNS, 2020, 46 (03) : 682 - 686
  • [44] Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States
    Hsu, Derek Y.
    Brieva, Joaquin
    Silverberg, Nanette B.
    Paller, Amy S.
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (05) : 811 - +
  • [45] A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    Abulatan, Isaac T.
    Ben-David, Sage G.
    Morales-Colon, Lery A.
    Beason, Elisabeth
    Fakoya, Adegbenro O.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [46] French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)
    Ingen-Housz-Oro, S.
    Matei, I.
    Gaillet, A.
    Gueudry, J.
    Zaghbib, K.
    Assier, H.
    Hua, C.
    Bensaid, B.
    Colin, A.
    Ouedraogo, R.
    Redlich, J.
    Courtois, E.
    Chazelas, K.
    Sbidian, E.
    Nakad, L.
    Bequignon, E.
    Terkmane, N.
    Gaultier, F.
    Schlemmer, F.
    Do-Pham, G.
    Barbaud, A.
    Lebrun-Vignes, B.
    Hoffmann, C.
    Mahe, P. -j.
    Le Floch, R.
    Bernier, C.
    Vabres, B.
    Milpied, B.
    Delcampe, A.
    Tetart, F.
    Tauber, M.
    Staumont-Salle, D.
    Dezoteux, F.
    Descamps, V
    Misery, L.
    Bursztejn, A. -c.
    Dereure, O.
    Amazan, E.
    Le Bidre, E.
    Le Pallec, S.
    Lagier, C.
    Laroche, A.
    Ferrat, E.
    Wolkenstein, P.
    de Prost, N.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2024, 151 (02):
  • [47] Stevens-Johnson syndrome and toxic epidermal necrolysis in Hong Kong
    Cheung, Christina M. T.
    Chang, Mimi M.
    Li, Joshua J. X.
    Chan, Agnes W. S.
    HONG KONG MEDICAL JOURNAL, 2024, 30 (02) : 102 - 109
  • [48] Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    Marianne Lerch
    Carlo Mainetti
    Benedetta Terziroli Beretta-Piccoli
    Thomas Harr
    Clinical Reviews in Allergy & Immunology, 2018, 54 : 147 - 176
  • [49] Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study
    Martin-Merino, Elisa
    de Abajo, Francisco J.
    Gil, Miguel
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (06) : 759 - 766
  • [50] Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide
    Vivar, Karina L.
    Mancl, Kimberly
    Seminario-Vidal, Lucia
    CLINICAL CASE REPORTS, 2018, 6 (02): : 258 - 261